Drug intelligence / Profile preview

CTL0901 + CTL0902

Development stage: Unknown
Lead developer: Celltrion
Modality: Small Molecules
Administration: Oral

Overview

CTL0901 + CTL0902 is an investigational **combination therapy** comprising two small molecule drugs, **CTL0901** and **CTL0902**, developed by Celltrion. Both agents are currently under evaluation primarily for their pharmacokinetic interactions, safety, and tolerability when administered alone and in combination in healthy adult volunteers in a phase 1 clinical context. No specific mechanism of action, clinical indication beyond “healthy, subjective” (healthy volunteers), or target disease has been disclosed publicly for either CTL0901 or CTL0902 as of the latest available data.

Beyond the preview

Go deeper on CTL0901 + CTL0902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTL0901 + CTL0902.

Explore the full profile